137 related articles for article (PubMed ID: 35667631)
1. Succinate Buffer in Biologics Products: Real-world Formulation Considerations, Processing Risks and Mitigation Strategies.
Ukidve A; Rembert KB; Vanipenta R; Dorion P; Lafarguette P; McCoy T; Saluja A; Suryanarayanan R; Patke S
J Pharm Sci; 2023 Jan; 112(1):138-147. PubMed ID: 35667631
[TBL] [Abstract][Full Text] [Related]
2. The effect of crystallizing and non-crystallizing cosolutes on succinate buffer crystallization and the consequent pH shift in frozen solutions.
Sundaramurthi P; Suryanarayanan R
Pharm Res; 2011 Feb; 28(2):374-85. PubMed ID: 20927571
[TBL] [Abstract][Full Text] [Related]
3. Calorimetric and diffractometric evidence for the sequential crystallization of buffer components and the consequential pH swing in frozen solutions.
Sundaramurthi P; Shalaev E; Suryanarayanan R
J Phys Chem B; 2010 Apr; 114(14):4915-23. PubMed ID: 20302316
[TBL] [Abstract][Full Text] [Related]
4. Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr).
Ingram RL; Weiser SE
Drugs R D; 2023 Mar; 23(1):55-64. PubMed ID: 36811761
[TBL] [Abstract][Full Text] [Related]
5. Fundamentals of freeze-drying.
Nail SL; Jiang S; Chongprasert S; Knopp SA
Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
[TBL] [Abstract][Full Text] [Related]
6. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
Garidel P; Pevestorf B; Bahrenburg S
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
[TBL] [Abstract][Full Text] [Related]
7. Predicting the crystallization propensity of carboxylic acid buffers in frozen systems--relevance to freeze-drying.
Sundaramurthi P; Suryanarayanan R
J Pharm Sci; 2011 Apr; 100(4):1288-93. PubMed ID: 24081466
[TBL] [Abstract][Full Text] [Related]
8. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
[TBL] [Abstract][Full Text] [Related]
9. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
10. Self-buffering antibody formulations.
Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
[TBL] [Abstract][Full Text] [Related]
11. Effect of Formulation and Process Parameters on the Disproportionation of Indomethacin Sodium in Buffered Lyophilized Formulations.
Koranne S; Thakral S; Suryanarayanan R
Pharm Res; 2018 Jan; 35(1):21. PubMed ID: 29305664
[TBL] [Abstract][Full Text] [Related]
12. Effect of cryoprotectants on freezing, lyophilization, and storage of lyophilized recombinant alpha 1-antitrypsin formulations.
Vemuri S; Yu CD; Roosdorp N
PDA J Pharm Sci Technol; 1994; 48(5):241-6. PubMed ID: 8000898
[TBL] [Abstract][Full Text] [Related]
13. Glycine crystallization in frozen and freeze-dried systems: effect of pH and buffer concentration.
Varshney DB; Kumar S; Shalaev EY; Sundaramurthi P; Kang SW; Gatlin LA; Suryanarayanan R
Pharm Res; 2007 Mar; 24(3):593-604. PubMed ID: 17245648
[TBL] [Abstract][Full Text] [Related]
14. Investigation of freeze/thaw-related quality attributes of a liquid biopharmaceutical formulation: the role of saccharide excipients.
Zhou R; Schlam RF; Yin S; Gandhi RB; Adams ML
PDA J Pharm Sci Technol; 2012; 66(3):221-35. PubMed ID: 22634588
[TBL] [Abstract][Full Text] [Related]
15. The formation and effect of mannitol hemihydrate on the stability of monoclonal antibody in the lyophilized state.
Anko M; Bjelošević M; Planinšek O; Trstenjak U; Logar M; Ahlin Grabnar P; Brus B
Int J Pharm; 2019 Jun; 564():106-116. PubMed ID: 30999044
[TBL] [Abstract][Full Text] [Related]
16. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Phosphate Buffered Saline (PBS) in Frozen State and after Freeze-Drying.
Thorat AA; Suryanarayanan R
Pharm Res; 2019 May; 36(7):98. PubMed ID: 31087169
[TBL] [Abstract][Full Text] [Related]
18. Buffer capacity of biologics--from buffer salts to buffering by antibodies.
Karow AR; Bahrenburg S; Garidel P
Biotechnol Prog; 2013; 29(2):480-92. PubMed ID: 23296746
[TBL] [Abstract][Full Text] [Related]
19. Novel Mechanism of Glass Delamination in Type 1A Borosilicate Vials Containing Frozen Protein Formulations.
Jiang G; Goss M; Li G; Jing W; Shen H; Fujimori K; Le L; Wong L; Wen ZQ; Nashed-Samuel Y; Riker K; Germansderfer A; Tsang P; Ricci M
PDA J Pharm Sci Technol; 2013; 67(4):323-35. PubMed ID: 23872443
[TBL] [Abstract][Full Text] [Related]
20. Ultrasonication as a potential tool to predict solute crystallization in freeze-concentrates.
Ragoonanan V; Suryanarayanan R
Pharm Res; 2014 Jun; 31(6):1512-24. PubMed ID: 24398694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
